Floatz logo

Evofosfamide

Advanced Myelofibrosis

Threshold PharmaceuticalsSmall moleculePhase 1Dormant
CC
47/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
32/ 100
Competitive Position
95/ 100

Competitive context

49 Active assets in the Advanced Myelofibrosis cohort.

Asset / SponsorPhaseRating
Anti-Thymoglobulin, Rabbit
Fred Hutchinson Cancer Center
Phase 2BB
CYCLOSPORIN A
City of Hope Medical Center
Phase 2B
Cyclophosphamide
City of Hope Medical Center
Phase 3B
Busulphan
City of Hope Medical Center
Phase 2B
Fludarabine
Center for International Blood and Marrow Transplant Research
Phase 3B

View all 50 →

Same molecule, other indications

Evofosfamide is also rated in:

pancreatic adenocarcinomaDormant
B
Indicative ·
63 / 100
View asset →
pancreatic neoplasmDormant
B
Indicative ·
56 / 100
View asset →
neuroendocrine neoplasmDormant
CCC
Indicative ·
54 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →